leadf
logo-loader
viewTodos Medical Ltd.

Todos trademarks Tollovid for dietary supplement NLC-001 and strikes distribution deal with The Alchemists Kitchen

Todos has struck a private label and distribution agreement with The Alchemist’s Kitchen, in New York to sell Tollovid under its Plant Alchemy brand

Todos Medical Ltd. - Todos trademarks Tollovid for dietary supplement NLC-001 and strikes distribution deal with The Alchemists Kitchen
Alchemist’s Kitchen CEO Lou Sagar said Tollovid certainly is a unique asset in the botanical wellness space and include a 3CL protease inhibitor that could help support immunity

Todos Medical Ltd (OTCQB:TOMDF) announced on Thursday that it has selected the brand name Tollovid for its patented dietary supplement NLC-001, which is a blend of plant extracts that include a 3CL protease inhibitor that could help support strong immunity.

Rehovot, Israel-based Todos Medical noted that 3CL protease plays “a vital role” in the intracellular replication of coronaviruses, and 3CL protease inhibition is being evaluated as a potential therapeutic target for COVID-19 by several groups, including Pfizer Inc (NYSE:PFE).

In September, Todos licensed the exclusive worldwide distribution rights (excluding Israel) for Tollovid from its joint venture partner NLC Pharma.

READ: Todos Medical announces completion of instrument validation in its mobile lab division

Concurrently, Todos revealed it has struck a private label and distribution agreement with The Alchemist’s Kitchen, in SoHo, in New York to sell Tollovid under its Plant Alchemy brand. The New-York-based company will train its herbalists to “educate consumers on how adding Tollovid to their immune-boosting strategy could potentially lead to improved outcomes in the face of circulating coronaviruses.”

The Alchemist’s Kitchen has a significant online presence has been featured in several high-profile educational series, including Dr Sanjay Gupta’s CBD and cannabis specials on CNN.

“Tollovid certainly is a unique asset in the botanical wellness space, and we are very pleased to be the first to bring this product to market in the United States,” said The Alchemist’s Kitchen CEO Lou Sagar in a statement.

“It’s clear there has been a tremendous amount of science developed around Tollovid as it relates to 3CL inhibition, and we believe this could be an important mechanism during this critical time heading into the colder months of the year where people will congregate indoors more often.”

Sagar noted that The Alchemist’s Kitchen is always looking to be on “the cutting edge of innovation in the botanical wellness space,” and Tollovid certainly “reinforces our market-leading position.”

“We are excited to have selected the brand name Tollovid for NLC-001 and to be partnering with The Alchemist’s Kitchen to bring this important immune-boosting dietary supplement into the marketplace at this critical time in the United States,” said Todos Medical CEO Gerald E Commissiong.

“Some of the most promising data in the scientific literature to date in combatting coronaviruses has been generated by dietary supplements that help reinforce the body’s ability to respond to potential challenges from a coronavirus infection … We believe Tollovid could be an important part of an immune-boosting strategy.”

Todos Medical develops diagnostic solutions to screen for a variety of cancers and neurodegenerative disorders, but it has recently pivoted to the coronavirus (COVID-19) PCR testing space and won a string of high-value contracts.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Todos Medical Ltd.

Price: 0.055 USD

OTCQB:TOMDF
Market: OTCQB
Market Cap: $11.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Todos Medical reveals positive clinical proof of concept data from its rapid...

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the group has “positive clinical proof of concept data” from its lab-based rapid SARS-CoV-2 3CL protease diagnostic test in collaboration with its joint venture partner NLC Pharma. Commissiong says now, the group is...

1 week, 3 days ago

3 min read